Sudeep Pharma Limited has submitted its Q2FY26 Result Presentation, following up on its earlier intimation regarding the Earnings Call scheduled for Monday, December 22, 2025, at 11:30 a.m. The call aims to discuss the operational and financial performance for the quarter and half-year ended September 30, 2025. The presentation, which is also hosted on the company's website (https://www.sudeeppharma.com/), provides an overview of the company's performance and strategic initiatives. Sudeep Pharma, a manufacturer of specialty ingredients for the pharmaceutical, food, and nutrition industries, highlighted its successful IPO listing on BSE and NSE on November 28, 2025. The company detailed its journey from pharma excipients to specialty ingredients, its corporate structure, and its competitive strengths including proprietary technologies and regulatory-certified infrastructure. Financially, for FY25, the company reported Revenues of ₹502 crore, EBITDA of ₹199 crore (39.7% margin), PAT of ₹139 crore (27.6% margin), ROCE of 29.5%, and ROE of 28.1%. For Q2 FY26, Total Income was ₹172.8 crore, EBITDA ₹65.6 crore (38.0% margin), and PAT ₹46.8 crore (27.1% margin). For H1 FY26, Total Income was ₹302.9 crore, EBITDA ₹114.7 crore (37.9% margin), and PAT ₹78.0 crore (25.8% margin). Key growth levers include organic growth through a new greenfield expansion at Nandesari (expected commissioning by Q4 FY26 with a capex of ~₹150 crore) and leveraging mineral chemistry expertise for battery materials, with a facility planned at Dahej, Gujarat. Inorganic growth is being pursued through the acquisition of an 85% stake in Nutrition Supplies Services (NSS), which is expected to enhance formulation capabilities and expand global customer reach. The company also noted the successful integration of NSS and the initiation of warehousing operations in the USA and Europe.